Gamcemetinib
Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM) . Gamcemetinib is extracted from patent WO2020236636, compound 1[1].
Product Specifications
CAS Number
1887069-10-4
Product Name Alternative
CC-99677
UNSPSC
12352005
Target
MAPKAPK2 (MK2)
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/gamcemetinib.html
Concentration
10mM
Purity
99.06
Solubility
DMSO : 37.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1C2=C(NC[C@H](N1)C)C3=C(S2)C=CC4=NC(OC5=NC(Cl)=NC=C5COCC)=CC=C34
Molecular Formula
C22H20ClN5O3S
Molecular Weight
469.94
References & Citations
[1]WO2020236636
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
FOLH1 / PSMA (Prostate Epithelial Marker) (FOLH1/2354), CF594 conjugate, 0.1mg/mL
1-Phenyl-N-propylpentan-2-amine Hydrochloride
Transthyretin (Prealbumin) (CPTC-TTR-1), CF594 conjugate, 0.1mg/mL
